Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: a case report.
Acute graft-versus-host disease (GVHD) following orthotopic liver transplantation is a rare but severe disease with a 75% death rate in adults. Various therapeutic strategies have been proposed for steroid-refractory GVHD, but there is still no consensus. Tumor necrosis factor-alpha is a key inflammatory cytokine involved in acute GVHD physiopathology, and infliximab has shown encouraging results for the treatment of acute GVHD following hematopoietic stem cell transplantation. We report the first case of acute GVHD following liver transplantation that was refractory to steroids and anti-lymphocyte globulin but was successfully treated with infliximab.
Piton
Gaël
G
Service d'Hépatologie, Université de Franche Comté et Centre Hospitalier Universitaire de Besançon, Besançon, France.
Larosa
Fabrice
F
Minello
Anne
A
Becker
Marie-Claude
MC
Mantion
Georges
G
Aubin
François
F
Deconinck
Eric
E
Hillon
Patrick
P
Di Martino
Vincent
V
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D000069285:Infliximab; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D012074:Remission Induction; D013256:Steroids / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab